Assessing Patient-Reported Financial, Social, and Time Toxicity in Early-Phase Cancer Clinical Trials in Australia Through a Prospective Multicenter Nonrandomized Cohort Study We conducted a ...
Medically reviewed by Matthew Wosnitzer, MD Key Takeaways Most prostate cancers become castration-resistant in about two to ...
Zydus Lifesciences on Wednesday said it has launched a biosimilar for the treatment of osteoporosis and the prevention of skeletal complications in cancer patients.      The company has launched ...